Together, these findings suggest that tumor- and stromal-derived lncRNAs may disrupt IL-2-mediated immune activation at multiple levels—both by reducing IL-2 production and by impairing IL-2 receptor signaling—thereby contributing to immune evasion within the tumor microenvironment. Here, IL2 is linked to neoplasm.